Article Text

Download PDFPDF
High dose intravenous steroid therapy for severe posterior segment uveitis in Behçet's disease
  1. E Toker,
  2. H Kazokoğlu,
  3. N Acar
  1. Marmara University Medical School, Department of Ophthalmology
  1. Correspondence to: Ebru Toker, İnönü cad, Yildiz sok, STFA Bloklari, B-6, Daire 13, Kozyatağý, 81090, İstanbul, Turkey; aetoker{at}superonline.com

Abstract

Aim: To evaluate the safety and effectiveness of high dose intravenous steroid therapy (HDIST) in Behçet's disease patients with severe posterior segment uveitis attacks.

Methods: Five patients with ocular Behçet's disease were treated with HDIST for severe posterior segment attacks. Two patients had vasculitis, one patient had papillitis, and the other two had retinitis; four patients also had accompanying severe vitritis. The visual acuities and improvement in ocular signs after HDIST were evaluated.

Results: During HDIST, patients had no systemic complications caused by treatment. All patients responded to HDIST with evidence of a decrease in intraocular inflammatory activity and improved visual acuities within a mean time of 7 (1–15) days of commencing treatment. During follow up three out of five patients had new posterior segment attacks.

Conclusion: HDIST is effective in controlling severe, vision threatening acute posterior segment Behçet's uveitis attacks and in improving visual function in a short period of time

  • Behçet's disease
  • uveitis
  • high dose intravenous steroid therapy

Statistics from Altmetric.com

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.